Back to News
Market Impact: 0.2
Lilly Q3 Profit Rises 16%; Lifts FY26 Sales View, Trims Adjusted Earnings Outlook
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Eli Lilly reported higher third-quarter profit and revenue, driven primarily by Mounjaro and Zepbound. The article provides no financial figures or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
LLY0.65
More News
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Lilly’s obesity drug strength fuels record rally, Wall Street optimism
- Nasdaq futures slide as mixed Big Tech results test AI trade
- Stocks making the biggest moves midday: ADT, Alphabet, Caterpillar, Eli Lilly, Chipotle & more